Originally published as JCO Early Release 10.1200/JCO.2002.06.020 on July 1 2002

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Winer, E. P. Articles by Browman, G. P. Search for Related Content PubMed PubMed Citation Articles by Winer, E. P. Articles by Browman, G. P. Social Bookmarking                            What's this?

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002

From the American Society of Clinical Oncology, Alexandria, VA.

Address reprint requests to American Society of Clinical Oncology, Health Services Research Department, 1900 Duke St, Suite 200, Alexandria, VA 22314; email: guidelines{at}asco.orgThis article was published online ahead of print at www.jco.org.

OBJECTIVE: To conduct an evidence-based technology assessment to determine whether the routine use of anastrozole or any of the aromatase inhibitors in the adjuvant breast cancer setting is appropriate for broad-based conventional use in clinical practice.

POTENTIAL INTERVENTIONS: Anastrozole, letrozole, and exemestane.

OUTCOMES: Outcomes of interest include breast cancer incidence, breast cancer-specific survival, overall survival, and net health benefit.

EVIDENCE: A comprehensive, formal literature review was conducted for relevant topics and is detailed in the text. Testimony was collected from invited experts and interested parties. The American Society of Clinical Oncology (ASCO)–prescribed technology assessment procedure was followed.

BENEFITS/HARMS: The ASCO panel recognizes that a woman and her physician’s decision regarding adjuvant hormonal therapy is complex and will depend on the importance and weight attributed to information regarding both cancer and non–cancer-related risks and benefits.

CONCLUSION: The panel was influenced by the compelling, extensive, and long-term data available on tamoxifen. Overall, the panel considers the results of the Arimidex (anastrozole) or Tamoxifen Alone or in Combination (ATAC) trial and the extensive supporting data to be very promising but insufficient to change the standard practice at this time (May 2002). A 5-year course of adjuvant tamoxifen remains the standard therapy for women with hormone receptor–positive breast cancer. The panel recommends that physicians discuss the available information with patients, and, in making a decision, acknowledge that treatment approaches can change over time. Individual health care providers and their patients will need to come to their own conclusions, with careful consideration of all of the available data. (Specific questions addressed by the panel are summarized in Appendix 3.)

VALIDATION: The conclusions of the panel were endorsed by the ASCO Health Services Research Committee and the ASCO Board of Directors.

SPONSOR: American Society of Clinical Oncology.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M.F.G. Verberg, N.S. Macklon, G. Nargund, R. Frydman, P. Devroey, F.J. Broekmans, and B.C.J.M. Fauser Mild ovarian stimulation for IVF Hum. Reprod. Update, January 1, 2009; 15(1): 13 - 29. [Abstract] [Full Text] [PDF]

				M. E. Cazzaniga, G. Mustacchi, P. Pronzato, A. De Matteis, F. Di Costanzo, I. Floriani, and On behalf of the NORA Study Group Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study Ann. Onc., December 1, 2007; 18(12): 1976 - 1980. [Abstract] [Full Text] [PDF]

				S. Chen, S.-R. Oh, S. Phung, G. Hur, J. J. Ye, S. L. Kwok, G. E. Shrode, M. Belury, L. S. Adams, and D. Williams Anti-Aromatase Activity of Phytochemicals in White Button Mushrooms (Agaricus bisporus) Cancer Res., December 15, 2006; 66(24): 12026 - 12034. [Abstract] [Full Text] [PDF]

				E. V. McCloskey Aromatase Inhibitors and Bone Health IBMS BoneKEy, June 1, 2006; 3(6): 5 - 13. [Abstract] [Full Text] [PDF]

				I. Kijima, S. Phung, G. Hur, S.-L. Kwok, and S. Chen Grape Seed Extract Is an Aromatase Inhibitor and a Suppressor of Aromatase Expression Cancer Res., June 1, 2006; 66(11): 5960 - 5967. [Abstract] [Full Text] [PDF]

				A. U. Buzdar and J. Cuzick Optimum Use of Aromatase Inhibitors in the Adjuvant Treatment of Early Breast Cancer J. Clin. Oncol., November 20, 2005; 23(33): 8544 - 8546. [Full Text] [PDF]

				M. Cianfrocca and W. J. Gradishar Controversies in the Therapy of Early Stage Breast Cancer Oncologist, November 1, 2005; 10(10): 766 - 779. [Abstract] [Full Text] [PDF]

				B. S. Mann, J. R. Johnson, R. Kelly, R. Sridhara, G. Williams, and R. Pazdur Letrozole in the Extended Adjuvant Treatment of Postmenopausal Women with History of Early-Stage Breast Cancer Who Have Completed 5 Years of Adjuvant Tamoxifen Clin. Cancer Res., August 15, 2005; 11(16): 5671 - 5677. [Abstract] [Full Text] [PDF]

				R. Kudachadkar and R. M. O'Regan Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer CA Cancer J Clin, May 1, 2005; 55(3): 145 - 163. [Abstract] [Full Text] [PDF]

				T. Itoh, K. Karlsberg, I. Kijima, Y.-C. Yuan, D. Smith, J. Ye, and S. Chen Letrozole-, Anastrozole-, and Tamoxifen-Responsive Genes in MCF-7aro Cells: A Microarray Approach Mol. Cancer Res., April 1, 2005; 3(4): 203 - 218. [Abstract] [Full Text] [PDF]

				K. Strasser-Weippl and P. E. Goss Advances in Adjuvant Hormonal Therapy for Postmenopausal Women J. Clin. Oncol., March 10, 2005; 23(8): 1751 - 1759. [Full Text] [PDF]

				E. P. Winer, C. Hudis, H. J. Burstein, A. C. Wolff, K. I. Pritchard, J. N. Ingle, R. T. Chlebowski, R. Gelber, S. B. Edge, J. Gralow, et al. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004 J. Clin. Oncol., January 20, 2005; 23(3): 619 - 629. [Abstract] [Full Text] [PDF]

				J. N. Ingle Endocrine Therapy Trials of Aromatase Inhibitors for Breast Cancer in the Adjuvant and Prevention Settings Clin. Cancer Res., January 15, 2005; 11(2): 900s - 905s. [Abstract] [Full Text] [PDF]

				B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]

				A. Buzdar and C. Macahilig How Rapidly Do Oncologists Respond to Clinical Trial Data? Oncologist, January 1, 2005; 10(1): 15 - 21. [Abstract] [Full Text] [PDF]

				J. S. Tobias Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention Ann. Onc., December 1, 2004; 15(12): 1738 - 1747. [Abstract] [Full Text] [PDF]

				International Breast Cancer Study Group Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93 Ann. Onc., December 1, 2004; 15(12): 1749 - 1759. [Abstract] [Full Text] [PDF]

				S. Chen, M. Cho, K. Karlsberg, D. Zhou, and Y.-C. Yuan Biochemical and Biological Characterization of a Novel Anti-aromatase Coumarin Derivative J. Biol. Chem., November 12, 2004; 279(46): 48071 - 48078. [Abstract] [Full Text] [PDF]

				K. L Jones and A. U Buzdar A review of adjuvant hormonal therapy in breast cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 391 - 406. [Abstract] [Full Text] [PDF]

				N Angelopoulos, V Barbounis, S Livadas, D Kaltsas, and G Tolis Effects of estrogen deprivation due to breast cancer treatment Endocr. Relat. Cancer, September 1, 2004; 11(3): 523 - 535. [Abstract] [Full Text] [PDF]

				ESHRE Capri Workshop Group Hormones and breast cancer Hum. Reprod. Update, July 1, 2004; 10(4): 281 - 293. [Abstract] [Full Text] [PDF]

				M. Cristofanilli and G. N. Hortobagyi Breast Cancer Highlights: Key Findings from the San Antonio Breast Cancer Symposium: A U.S. Perspective Oncologist, July 1, 2004; 9(4): 471 - 478. [Abstract] [Full Text] [PDF]

				K. B. Bouker, T. C. Skaar, D. R. Fernandez, K. A. O'Brien, R. B. Riggins, D. Cao, and R. Clarke Interferon Regulatory Factor-1 Mediates the Proapoptotic but Not Cell Cycle Arrest Effects of the Steroidal Antiestrogen ICI 182,780 (Faslodex, Fulvestrant) Cancer Res., June 1, 2004; 64(11): 4030 - 4039. [Abstract] [Full Text] [PDF]

				E. R. Kisanga, J. Gjerde, A. Guerrieri-Gonzaga, F. Pigatto, A. Pesci-Feltri, C. Robertson, D. Serrano, G. Pelosi, A. Decensi, and E. A. Lien Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial Clin. Cancer Res., April 1, 2004; 10(7): 2336 - 2343. [Abstract] [Full Text] [PDF]

				T. Shenkier, L. Weir, M. Levine, I. Olivotto, T. Whelan, and L. Reyno Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer Can. Med. Assoc. J., March 16, 2004; 170(6): 983 - 994. [Abstract] [Full Text] [PDF]

				E. T. Eng, J. Ye, D. Williams, S. Phung, R. E. Moore, M. K. Young, U. Gruntmanis, G. Braunstein, and S. Chen Suppression of Estrogen Biosynthesis by Procyanidin Dimers in Red Wine and Grape Seeds Cancer Res., December 1, 2003; 63(23): 8516 - 8522. [Abstract] [Full Text] [PDF]

				P. E. Goss, J. N. Ingle, S. Martino, N. J. Robert, H. B. Muss, M. J. Piccart, M. Castiglione, D. Tu, L. E. Shepherd, K. I. Pritchard, et al. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer N. Engl. J. Med., November 6, 2003; 349(19): 1793 - 1802. [Abstract] [Full Text] [PDF]

				H. J. Burstein Beyond Tamoxifen -- Extending Endocrine Treatment for Early-Stage Breast Cancer N. Engl. J. Med., November 6, 2003; 349(19): 1857 - 1859. [Full Text] [PDF]

				C. Osipo, C. Gajdos, H. Liu, B. Chen, and V. C. Jordan Paradoxical Action of Fulvestrant in Estradiol-Induced Regression of Tamoxifen-Stimulated Breast Cancer J Natl Cancer Inst, November 5, 2003; 95(21): 1597 - 1608. [Abstract] [Full Text] [PDF]

				B. E. Hillner, J. N. Ingle, R. T. Chlebowski, J. Gralow, G. C. Yee, N. A. Janjan, J. A. Cauley, B. A. Blumenstein, K. S. Albain, A. Lipton, et al. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer J. Clin. Oncol., November 1, 2003; 21(21): 4042 - 4057. [Abstract] [Full Text] [PDF]

				A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, and H.-J. Senn Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer J. Clin. Oncol., September 1, 2003; 21(17): 3357 - 3365. [Abstract] [Full Text] [PDF]

				A. U. Buzdar Advances in Endocrine Treatments for Postmenopausal Women with Metastatic and Early Breast Cancer Oncologist, August 1, 2003; 8(4): 335 - 341. [Abstract] [Full Text] [PDF]

				C. E. Holmes and H. B. Muss Diagnosis and Treatment of Breast Cancer in the Elderly CA Cancer J Clin, July 1, 2003; 53(4): 227 - 244. [Abstract] [Full Text]

				E. P. Winer, C. Hudis, H. J. Burstein, J. Bryant, R. T. Chlebowski, J. N. Ingle, S. B. Edge, E. P. Mamounas, R. Gelber, J. Gralow, et al. American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting J. Clin. Oncol., July 1, 2003; 21(13): 2597 - 2599. [Full Text] [PDF]

				I. E. Smith and M. Dowsett Aromatase Inhibitors in Breast Cancer N. Engl. J. Med., June 12, 2003; 348(24): 2431 - 2442. [Full Text] [PDF]

				K. Wu and P. Brown Is Low-Dose Tamoxifen Useful for the Treatment and Prevention of Breast Cancer? J Natl Cancer Inst, June 4, 2003; 95(11): 766 - 767. [Full Text] [PDF]

				A. Decensi, C. Robertson, G. Viale, F. Pigatto, H. Johansson, E. R. Kisanga, P. Veronesi, R. Torrisi, M. Cazzaniga, S. Mora, et al. A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers J Natl Cancer Inst, June 4, 2003; 95(11): 779 - 790. [Abstract] [Full Text] [PDF]

				B. L. Riggs and L. C. Hartmann Selective Estrogen-Receptor Modulators -- Mechanisms of Action and Application to Clinical Practice N. Engl. J. Med., February 13, 2003; 348(7): 618 - 629. [Full Text] [PDF]

				A. Brodie, D. Jelovac, and B. J. Long Predictions from a Preclinical Model: Studies of Aromatase Inhibitors and Antiestrogens Clin. Cancer Res., January 1, 2003; 9(1): 455s - 459s. [Abstract] [Full Text]

				J. A. Ligibel and E. P. Winer Clinical Differences among the Aromatase Inhibitors Clin. Cancer Res., January 1, 2003; 9(1): 473s - 479s. [Abstract] [Full Text]

				J. N. Ingle Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Clin. Cancer Res., January 1, 2003; 9(1): 480s - 485s. [Abstract] [Full Text]

				I. C. Henderson A Rose Is No Longer a Rose J. Clin. Oncol., August 15, 2002; 20(16): 3365 - 3368. [Full Text] [PDF]

				R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343. [Abstract] [Full Text] [PDF]